NextCure Shares Outstanding History (NXTC)
NextCure reported 3.5M shares outstanding at the end of fiscal 2025.
View full NextCure company overviewNextCure annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 3.5M | 1.2M | +50.20% |
| 2024 | 2024-12-31 | 2.3M | 2.3M | +16236.55% |
| 2023 | 2023-12-31 | 14,286.35 | 65.787 | +0.46% |
| 2022 | 2022-12-31 | 14,220.562 | 47.892 | +0.34% |
| 2021 | 2021-12-31 | 14,172.67 | 57.444 | +0.41% |
| 2020 | 2020-12-31 | 14,115.227 | 35.606 | +0.25% |
| 2019 | 2019-12-31 | 14,079.621 | 13,375.717 | +1900.22% |
| 2018 | 2018-12-31 | 703.904 | — | — |
NextCure quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 4.1M | 4.1M | +339883.55% |
| Q1 2026 | 2026-03-31 | 3.6M | 3.6M | +25058.30% |
| Q4 2025 | 2025-12-31 | 3.5M | 3.5M | +24347.44% |
| Q3 2025 | 2025-09-30 | 214,088.8 | 199,765.17 | +1394.65% |
| Q2 2025 | 2025-06-30 | 1,196.808 | −13,126.822 | −91.64% |
| Q1 2025 | 2025-03-31 | 14,339.422 | 52.765 | +0.37% |
| Q4 2024 | 2024-12-31 | 14,339.422 | 53.072 | +0.37% |
| Q3 2024 | 2024-09-30 | 14,323.63 | 69.566 | +0.49% |
| Q2 2024 | 2024-06-30 | 14,323.63 | 69.566 | +0.49% |
| Q1 2024 | 2024-03-31 | 14,286.657 | 66.095 | +0.46% |
| Q4 2023 | 2023-12-31 | 14,286.35 | 65.787 | +0.46% |
| Q3 2023 | 2023-09-30 | 14,254.064 | 46.655 | +0.33% |
| Q2 2023 | 2023-06-30 | 14,254.064 | 46.655 | +0.33% |
| Q1 2023 | 2023-03-31 | 14,220.562 | 25.279 | +0.18% |
| Q4 2022 | 2022-12-31 | 14,220.562 | 47.892 | +0.34% |
| Q3 2022 | 2022-09-30 | 14,207.408 | 66.089 | +0.47% |
| Q2 2022 | 2022-06-30 | 14,207.408 | 70.292 | +0.50% |
| Q1 2022 | 2022-03-31 | 14,195.283 | 61.821 | +0.44% |
| Q4 2021 | 2021-12-31 | 14,172.67 | 57.444 | +0.41% |
| Q3 2021 | 2021-09-30 | 14,141.319 | 34.137 | +0.24% |
| Q2 2021 | 2021-06-30 | 14,137.116 | 46.543 | +0.33% |
| Q1 2021 | 2021-03-31 | 14,133.462 | 45.064 | +0.32% |
| Q4 2020 | 2020-12-31 | 14,115.227 | 35.606 | +0.25% |
| Q3 2020 | 2020-09-30 | 14,107.182 | 2,464.637 | +21.17% |
| Q2 2020 | 2020-06-30 | 14,090.573 | 2,460.613 | +21.16% |
| Q1 2020 | 2020-03-31 | 14,088.398 | 6,121.386 | +76.83% |
| Q4 2019 | 2019-12-31 | 14,079.621 | 13,991.985 | +15966.02% |
| Q3 2019 | 2019-09-30 | 11,642.545 | 11,554.909 | +13185.11% |
| Q2 2019 | 2019-06-30 | 11,629.96 | — | — |
| As of May 13, 2019 | 2019-05-13 | 7,967.011 | — | — |
| Q1 2019 | 2019-03-31 | 87.636 | — | — |
| Q4 2018 | 2018-12-31 | 87.636 | — | — |
NextCure shares outstanding trends
Over the last five reported fiscal years, NextCure's shares outstanding moved from 14,115.227 to 3.5M, a change of 3.5M. The latest reported quarter, Q2 2026, shows 4.1M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NextCure filings at SEC.gov ↗